https://socictopen.socict.org/files/original/27a5314808d80d45c149e2c83acea7c5.pdf 70dea144ce39adc59ab085129b4bb969 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review Creator An entity primarily responsible for making the resource Junxiong Pang, Minxian Wang, Ian Yi Han Ang, Sharon Hui Xuan Tan, Ruth Frances Lewis, Jacinta I-Pei Chen, Ramona A. Gutiérrez, Sylvia Xiao Wei Gwee, Pearleen Ee Yong Chua, Qian Yang, Xian Ying, Rowena KS Yap, Hao Yi Tan, Yik-Ying Teo, Chorh Chuan Tan, Alex R Cook, Jason Chin-Huat Yap, Li Yang Hsu Description An account of the resource Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource novel coronavirus, diagnostics, vaccine, treatments, global health, Outbreak, MERS-CoV, SARS-CoV Identifier An unambiguous reference to the resource within a given context DOI: 10.3390/jcm9030623 Source A related resource from which the described resource is derived Journal of Clinical Medicine Publisher An entity responsible for making the resource available MDPI AG Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine Language A language of the resource EN